Vowst Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increasing incidence of recurrent C. diff infections, limitations of traditional antibiotic therapies, clinical validation of microbiome therapeutics, rising hospital-acquired infection rates, improved regulatory pathways for live biotherapeutics.

The growth in the forecast period can be attributed to expansion of microbiome-based drug development, rising demand for non-antibiotic infection management, increasing investment in gut health research, growing adoption of precision microbiome therapies, advancements in oral biologic formulation technologies. Major trends in the forecast period include increasing adoption of microbiota-based therapeutics, rising focus on gut microbiome restoration therapies, growing use of oral live biotherapeutic products, expansion of targeted infection recurrence prevention, enhanced emphasis on antibiotic-adjunct treatments.

The increasing prevalence of Clostridioides difficile infections (CDIs) is expected to drive the growth of the Vowst market. Clostridioides difficile infections are caused by the bacterium *Clostridioides difficile*, which leads to inflammation of the colon and symptoms such as severe diarrhea, abdominal pain, and fever. The rising prevalence of CDIs is driven by widespread antibiotic use that disrupts gut microbiota, higher rates of healthcare-associated infections, aging populations with weaker immune systems, and the emergence of hypervirulent *C. difficile* strains. Vowst addresses CDIs by restoring the natural balance of gut bacteria, which is often disrupted by antibiotic treatment. For instance, in March 2023, the National Library of Medicine reported that Clostridioides difficile infections affect approximately 500,000 people annually in the United States, with about 30,000 deaths resulting from the infection. Therefore, the growing prevalence of CDIs is propelling the Vowst market.

A key trend in the Vowst market is the development of innovative therapies, such as antibacterial treatments for recurrent Clostridioides difficile infection (rCDI), aimed at improving patient outcomes and reducing recurrence rates. These treatments target and eliminate *C. difficile* bacteria in patients experiencing repeated infections. For example, in April 2023, Seres Therapeutics Inc., a US-based biotech company, in collaboration with Nestlé Health Science, a Switzerland-based pharmaceutical company, received FDA approval for Vowst (fecal microbiota spores, live-brpk). This orally administered microbiota-based therapy is designed to prevent recurrence of CDI in adults following antibacterial treatment for rCDI by restoring a healthy gut microbiome.

In August 2024, Nestlé Health Science acquired full control of the Vowst business from Seres Therapeutics for $175 million. This acquisition strengthens Nestlé Health Science’s capabilities in microbiome therapeutics and expands its portfolio of innovative treatments for gastrointestinal health, particularly for the prevention of recurrent Clostridioides difficile infections. Seres Therapeutics Inc. continues to develop Vowst as part of its focus on microbiome-based therapies.

Major companies operating in the vowst market are Seres Therapeutics Inc.

North America was the largest region in the vowst market in 2025. The regions covered in the vowst market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the vowst market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are influencing the vowst market by increasing costs of imported bioprocessing equipment, encapsulation technologies, cold-chain logistics materials, and quality testing systems required for live microbiota drug manufacturing. Healthcare providers in North America and Europe are most affected due to dependence on specialized imported production inputs. These tariffs are elevating manufacturing and distribution costs and may slow broader market adoption. However, they are also encouraging domestic biomanufacturing investments, regional production of microbiome therapeutics, and strengthened local supply chains for live biotherapeutic products.

The vowst market research report is one of a series of new reports that provides vowst market statistics, including vowst industry global market size, regional shares, competitors with a vowst market share, detailed vowst market segments, market trends and opportunities, and any further data you may need to thrive in the vowst industry. This vowst market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Vowst is a prescription medication containing live fecal microbiota spores, used to prevent the recurrence of *Clostridioides difficile* (C. diff) infections in adults following antibiotic treatment. It works by restoring beneficial gut bacteria, which helps inhibit the growth of C. diff and reduce the risk of reinfection.

The primary indications for Vowst include infectious diseases, gut microbiota restoration, and immune modulation. Infectious diseases are illnesses caused by pathogenic microorganisms such as bacteria, viruses, fungi, or parasites that can invade the body and spread directly or indirectly. Vowst is distributed through hospitals, specialty pharmacies, retail pharmacies, and online pharmacies, and is used by adult and geriatric patients.

The vowst market consists of sales of vowst capsules, microbiome diagnostics kits, gut health supplements, and fecal microbiota transplant (FMT) alternatives. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.